DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Discovery of a novel B-cell lymphoma 6 (BCL6)–corepressor interaction inhibitor by utilizing structure-based drug design

Journal Article · · Bioorganic and Medicinal Chemistry

Sponsoring Organization:
USDOE Office of Science (SC), Basic Energy Sciences (BES)
Grant/Contract Number:
AC02-05CH11231
OSTI ID:
1549649
Journal Information:
Bioorganic and Medicinal Chemistry, Journal Name: Bioorganic and Medicinal Chemistry Vol. 25 Journal Issue: 17; ISSN 0968-0896
Publisher:
ElsevierCopyright Statement
Country of Publication:
United Kingdom
Language:
English
Citation Metrics:
Cited by: 24 works
Citation information provided by
Web of Science

References (30)

The Ansamycin Antibiotic, Rifamycin SV, Inhibits BCL6 Transcriptional Repression and Forms a Complex with the BCL6-BTB/POZ Domain journal March 2014
Roles of BCL6 in normal and transformed germinal center B cells: BCL6 role in GC B cells journal April 2012
Discovery of high-affinity BCL6-binding peptide and its structure-activity relationship journal January 2017
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo journal April 2009
Predicting druggable binding sites at the protein–protein interface journal February 2009
Structure of a BCOR Corepressor Peptide in Complex with the BCL6 BTB Domain Dimer journal February 2008
The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT journal October 1998
MolProbity : all-atom structure validation for macromolecular crystallography journal December 2009
Features and development of Coot journal March 2010
Discovery of a B-Cell Lymphoma 6 Protein–Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach journal May 2017
Discovery of Pyrazolo[1,5- a ]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors journal May 2017
REFMAC 5 for the refinement of macromolecular crystal structures journal March 2011
Small-molecule protein-protein interaction inhibitors: Therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations journal October 2010
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma journal August 2016
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces journal December 2007
RNA interference targeting Bcl-6 ameliorates experimental autoimmune myasthenia gravis in mice journal January 2014
Control of Inflammation, Cytokine Expression, and Germinal Center Formation by BCL-6 journal April 1997
Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry journal March 2011
A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo journal April 2010
BCL-6 protein is expressed in germinal-center B cells journal July 1995
Critical Residues within the BTB Domain of PLZF and Bcl-6 Modulate Interaction with Corepressors journal March 2002
The CCP4 suite programs for protein crystallography journal September 1994
BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms journal September 2007
Signals that influence T follicular helper cell differentiation and function journal January 2010
MOLREP an Automated Program for Molecular Replacement journal December 1997
The solvatochromic comparison method. 3. Hydrogen bonding by some 2-nitroaniline derivatives journal May 1976
Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas journal January 2008
BCoR, a novel corepressor involved in BCL-6 repression journal July 2000
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR–ABL1 kinase inhibition journal May 2011
Mechanism of SMRT Corepressor Recruitment by the BCL6 BTB Domain journal December 2003